A mechanistic model of the intravitreal pharmacokinetics of large molecules and the pharmacodynamic suppression of ocular vascular endothelial growth factor levels by ranibizumab in patients with neovascular age-related macular degeneration

Molecular Pharmaceutics

Volumn 13, Issue 9, 2016, Pages 2941-2950

  Hutton Smith, Laurence A ^a   Gaffney, Eamonn A ^a   Byrne, Helen M ^a   Maini, Philip K ^a   Schwab, Dietmar ^b   Mazer, Norman A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

intravitreal; mechanistic modeling; neovascular age related macular degeneration; pharmacokinetics; ranibizumab; VEGF

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; MOLECULAR SIZE; MOLECULAR WEIGHT; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NONHUMAN; OCULAR TISSUE; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; STOICHIOMETRY; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; HAPLORHINI; INTRAVITREAL DRUG ADMINISTRATION; KINETICS; LEPORIDAE; METABOLISM; RAT; THEORETICAL MODEL; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HAPLORHINI; HUMANS; INTRAVITREAL INJECTIONS; KINETICS; MODELS, THEORETICAL; RABBITS; RANIBIZUMAB; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84971218492     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00849     Document Type: Article

References (37)

1. Bressler, N. M. Age-Related Macular Degeneration Is the Leading Cause of Blindness Arch Ophthalmol 2004, 291 (15) 1900-1901 10.1001/jama.291.15.1900
2. Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y. Ranibizumab for Neovascular Age-Related Macular Degeneration N. Engl. J. Med. 2006, 355 (14) 1419-1431 10.1056/NEJMoa054481
3. Penn, J. S.; Madan, A.; Caldwell, R. B.; Bartoli, M.; Caldwell, R. W.; Hartnett, M. E. Vascular Endothelial Growth Factor in Eye Disease Prog. Retinal Eye Res. 2008, 27 (4) 331-371 10.1016/j.preteyeres.2008.05.001
4. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of Ranibizumab, an Anti-Vascular Endothelial Growth Factor Antigen Binding Fragment, as Therapy for Neovascular Age-Related Macular Degeneration Retina 2006, 26 (8) 859-870 10.1097/01.iae.0000242842.14624.e7
5. Meyer, C. H.; Krohne, T. U.; Holz, F. G. Concentrations of Unbound Bevacizumab in the Aqueous of Untreated Fellow Eyes after a Single Intravitreal Injection in Humans Acta Ophthalmol. 2012, 90 (1) 68-70 10.1111/j.1755-3768.2009.01842.x
6. Krohne, T. U.; Eter, N.; Holz, F. G.; Meyer, C. H. Intraocular Pharmacokinetics of Bevacizumab after a Single Intravitreal Injection in Humans Am. J. Ophthalmol. 2008, 146 (4) 508-512 10.1016/j.ajo.2008.05.036
7. Mordenti, J.; Cuthbertson, R. A.; Ferrara, N.; Thomsen, K.; Berleau, L.; Licko, V.; Allen, P. C.; Valverde, C. R.; Meng, Y. G.; Fei, D. T. W.; Fourre, K. M.; Ryan, A. M. Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125 I-Labeled Full-Length and Fab Antibodies Following Intravitreal Administration Toxicol. Pathol. 1999, 27 (5) 536-544 10.1177/019262339902700507
8. Gaudreault, J.; Fei, D.; Rusit, J.; Suboc, P.; Shiu, V. Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration Invest. Ophthalmol. Visual Sci. 2005, 46 (2) 726-733 10.1167/iovs.04-0601
9. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Ezzat, M. K.; Singh, R. J. Pharmacokinetics of Intravitreal Ranibizumab (Lucentis) Ophthalmology 2007, 114 (12) 2179-2182 10.1016/j.ophtha.2007.09.012
10. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Singh, R. J. Pharmacokinetics of Intravitreal Bevacizumab (Avastin) Ophthalmology 2007, 114 (5) 855-859 10.1016/j.ophtha.2007.01.017
11. Krohne, T. U.; Liu, Z.; Holz, F. G.; Meyer, C. H. Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans Am. J. Ophthalmol. 2012, 154 (4) 682-686 10.1016/j.ajo.2012.03.047
12. Xu, L.; Lu, T.; Tuomi, L.; Jumbe, N.; Lu, J.; Eppler, S.; Kuebler, P.; Damico-Beyer, L. A.; Joshi, A. Pharmacokinetics of Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration: A Population Approach Invest. Ophthalmol. Visual Sci. 2013, 54 (3) 1616-1624 10.1167/iovs.12-10260
13. Gadkar, K.; Pastuskovas, C. V.; Le Couter, J. E.; Elliott, J. M.; Zhang, J.; Lee, C. V.; Sanowar, S.; Fuh, G.; Kim, H. S.; Lombana, T. N.; Spiess, C.; Nakamura, M.; Hass, P.; Shatz, W.; Meng, Y. G.; Scheer, J. M. Design and Pharmacokinetic Characterization of Novel Antibody Formats for Ocular Therapeutics Invest. Ophthalmol. Visual Sci. 2015, 56 (9) 5390-5400 10.1167/iovs.15-17108
14. Chuang, L.-H.; Wu, W.-C.; Yeung, L.; Wang, N.-K.; Hwang, Y.-S.; Chen, K.-J.; Kuo, J. Z.-C.; Lai, C.-C. Serum Concentration of Bevacizumab after Intravitreal Injection in Experimental Branch Retinal Vein Occlusion Ophthalmic Res. 2011, 45 (1) 31-35 10.1159/000315617
15. Muether, P. S.; Hermann, M. M.; Viebahn, U.; Kirchhof, B.; Fauser, S. Vascular Endothelial Growth Factor in Patients with Exudative Age-Related Macular Degeneration Treated with Ranibizumab Ophthalmology 2012, 119 (10) 2082-2086 10.1016/j.ophtha.2012.07.041
16. Muether, P. S.; Hermann, M. M.; Dröge, K.; Kirchhof, B.; Fauser, S. Long-Term Stability of Vascular Endothelial Growth Factor Suppression Time under Ranibizumab Treatment in Age-Related Macular Degeneration Am. J. Ophthalmol. 2013, 156 (5) 989 10.1016/j.ajo.2013.06.020
17. Saunders, D. J.; Muether, P. S.; Fauser, S. A Model of the Ocular Pharmacokinetics Involved in the Therapy of Neovascular Age-Related Macular Degeneration with Ranibizumab Br. J. Ophthalmol. 2015, 99, 1554-1559 10.1136/bjophthalmol-2015-306771
18. Papadopoulos, N.; Martin, J.; Ruan, Q.; Rafique, A.; Rosconi, M. P.; Shi, E.; Pyles, E. a.; Yancopoulos, G. D.; Stahl, N.; Wiegand, S. J. Binding and Neutralization of Vascular Endothelial Growth Factor (VEGF) and Related Ligands by VEGF Trap, Ranibizumab and Bevacizumab Angiogenesis 2012, 15 (2) 171-185 10.1007/s10456-011-9249-6
19. Missel, P. J. Simulating Intravitreal Injections in Anatomically Accurate Models for Rabbit, Monkey, and Human Eyes Pharm. Res. 2012, 29 (12) 3251-3272 10.1007/s11095-012-0721-9
20. Yang, J.; Wang, X.; Fuh, G.; Yu, L.; Wakshull, E.; Khosraviani, M.; Day, E. S.; Demeule, B.; Liu, J.; Shire, S. J.; Ferrara, N.; Yadav, S. Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A Mol. Pharmaceutics 2014, 11, 3421-3430 10.1021/mp500160v
21. Harpaz, Y.; Gerstein, M.; Chothia, C. Volume Changes on Protein Folding Structure 1994, 2 (7) 641-649 10.1016/S0969-2126(00)00065-4
22. Park, J.; Bungay, P. M.; Lutz, R. J.; Augsburger, J. J.; Millard, R. W.; Sinha Roy, A.; Banerjee, R. K. Evaluation of Coupled Convective-Diffusive Transport of Drugs Administered by Intravitreal Injection and Controlled Release Implant J. Controlled Release 2005, 105 (3) 279-295 10.1016/j.jconrel.2005.03.010
23. Bressloff, P. C.; Newby, J. M. Stochastic Models of Intracellular Transport Rev. Mod. Phys. 2013, 85 (1) 135-196 10.1103/RevModPhys.85.135
24. Meyer, C. H.; Krohne, T. U.; Holz, F. G. Intraocular Pharmacokinetics After A Single Intravitreal Iinjection Of 1.5 Mg Versus 3.0 Mg Of Bevacizumab In Humans Retina 2011, 31 (9) 1877-1884 10.1097/IAE.0b013e318217373c
25. Ferrara, N. Vascular Endothelial Growth Factor and Age-Related Macular Degeneration: From Basic Science to Therapy Nat. Med. 2010, 16 (10) 1107-1111 10.1038/nm1010-1107
26. Zhu, Q.; Ziemssen, F.; Henke-fahle, S.; Tatar, O.; Szurman, P.; Aisenbrey, S.; Schneiderhan-marra, N.; Xu, X.; Grisanti, S. Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization Ophthalmology 2008, 115, 1750-1756 10.1016/j.ophtha.2008.04.023
27. The MathWorks Inc. MATLAB User Guide R2015b: Global Optimization Toolbox, 2015.
28. Tasman, W.; Jaeger, E. A. Duane's Ophthalmology 2013; Lippincott Williams & Wilkins, 2013.
29. Fontana, S. T.; Brubaker, R. F. Volume and Depth of the Anterior Chamber in the Normal Aging Human Eye Arch. Ophthalmol. 1980, 98, 1803-1808 10.1001/archopht.1980.01020040655013
30. Toris, C. B.; Yablonski, M. E.; Wang, Y. L.; Camras, C. B. Aqueous Humor Dynamics in the Aging Human Eye Am. J. Ophthalmol. 1999, 127 (4) 407-412 10.1016/S0002-9394(98)00436-X
31. Sha, O.; Kwong, W. H. Postnatal Developmental Changes of Vitreous and Lens Volumes in Sprague-Dawley Rats Neuroembryol. Aging 2006, 4 (4) 183-188 10.1159/000118928
32. Ramanujan, S.; Pluen, A.; McKee, T. D.; Brown, E. B.; Boucher, Y.; Jain, R. K. Diffusion and Convection in Collagen Gels: Implications for Transport in the Tumor Interstitium Biophys. J. 2002, 83 (3) 1650-1660 10.1016/S0006-3495(02)73933-7
33. Bishop, P. N. Structural Macromolecules and Supramolecular Organisation of the Vitreous Gel Prog. Retinal Eye Res. 2000, 19 (3) 323-344 10.1016/S1350-9462(99)00016-6
34. Macchioni, A.; Ciancaleoni, G.; Zuccaccia, C.; Zuccaccia, D. Determining Accurate Molecular Sizes in Solution through NMR Diffusion Spectroscopy Chem. Soc. Rev. 2008, 37 (3) 479-489 10.1039/B615067P
35. Stuttfeld, E. Structural and Functional Characterization of the Extracellular Domain of Vascular Endothelial Growth Factor Receptors: Their Role in Receptor Activation and Use as Therapeutic Targets. Doctoral Dissertation, University of Basel, Basel, Switzerland, 2012.
36. Reille-Seroussi, M.; Gaucher, J.-F.; Desole, C.; Gagey-Eilstein, N.; Brachet, F.; Broutin, I.; Vidal, M.; Broussy, S. Vascular Endothelial Growth Factor Peptide Ligands Explored by Competition Assay and Isothermal Titration Calorimetry Biochemistry 2015, 54 (33) 5147-5156 10.1021/acs.biochem.5b00722
37. Davuluri, G.; Espina, V.; Petricoin, E. F.; Ross, M.; Deng, J.; Liotta, L. A.; Glaser, B. M. Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD Arch. Ophthalmol. 2009, 127 (5) 613-621 10.1001/archophthalmol.2009.88